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NaOBJECTIVES This study sought to examine whether the heart rate (HR) at which the force-frequency relationship (FFR)
slope peaks (critical HR) could be used to tailor HR response in chronic heart failure (CHF) patients with cardiac
pacemakers and whether this favorably inﬂuences exercise capacity.
BACKGROUND CHF secondary to left ventricular (LV) systolic dysfunction is characterized by blunting of the positive
relationship between HR and LV contractility known as the FFR.
METHODS This observational study was carried out in patients with CHF and healthy subjects with pacemaker
devices. The study assessed the 3 important features of the FFR (critical HR, peak contractility, and the FFR slope),
and their reproducibility was measured noninvasively using echocardiography. The investigators then undertook a
double-blind, randomized, controlled crossover study comparing the effects of tailored pacemaker rate-response
programming on the basis of the FFR with conventional rate-response programming on exercise time and maximal
oxygen consumption.
RESULTS The study enrolled 90 patients with CHF into the observational cohort study: mean age, 73.6  8.9 years;
mean left ventricular ejection fraction (LVEF), 33.5  10.9%. The study investigated 15 control subjects with normal LV
function (LVEF, 55.6  5.3%). The critical HR (103  22 beats/min vs. 126  15 beats/min; p ¼ 0.0002), peak
contractility (3.8  3.7 SBP/LVESVI vs. 9.8  4.1 SBP/LVESVI; p ¼ 0.0001), and the slope of the FFR (p < 1015) were
lower in patients with CHF than in control subjects. A total of 52 patients, with a mean LVEF of 32  11% on optimal
therapy, took part in the crossover study. Rate-response settings limiting HR rise to below the critical HR led to greater
exercise time (475  189 s vs. 425  196 s; p ¼ 0.003) and higher peak oxygen consumption (17.3  4.6 ml/kg/min vs.
16.6  4.7 ml/kg/min; p ¼ 0.01).
CONCLUSIONS A personalized approach to rate-response programming, determined using a reproducible noninvasive
method for assessing the FFR, improves exercise time in patients with CHF and pacemaker devices. (Bowditch Revisited:
Deﬁning the Optimum Heart Rate Range in Chronic Heart Failure; NCT02563873) (J Am Coll Cardiol HF 2018;6:105–13)
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106C haracterized by reduced exercisetolerance, chronic heart failure(CHF) secondary to left ventricular
(LV) systolic dysfunction (LVSD) has a dele-
terious impact on quality of life in millions
of individuals worldwide (1). Advances in
our understanding of the pathophysiology
of CHF have informed the development of
drugs and devices, including cardiac
resynchronization therapy (CRT), that
have substantially improved life expectancy
(2–5). Nonetheless, many patients with CHF
and CRT remain signiﬁcantly limited (6).
An important determinant of exercise
performance is thought to be LV contrac-
tility, which in 1871 was shown to be posi-tively coupled to increments in heart rate (HF) (7). As
HR increases in healthy humans, LV contractility and
stroke volume increase simultaneously (8). Using
invasive measurements, we and other investigators
have shown that this critical physiological response,
described as the force-frequency relationship (FFR),
becomes ﬂattened in patients with CHF, with a
decline in LV contractility occurring above a certain
HR (9,10). We hypothesized that by deﬁning an in-
dividual’s FFR noninvasively (and in particular the
peak of this response before the decline in contrac-
tility characteristic in CHF), it may be possible to
tailor individual pacing algorithms to exploit a pa-
tient’s unique physiology. Here we show that it is
possible to use a noninvasive, reproducible approach
to deﬁne the peak of the force-frequency curve of
patients with CHF with CRT devices in situ and use
this information to improve exercise capacity.
ureSEE PAGE 114METHODS
This paper describes the ﬁndings of 1 observational
and 1 interventional study.
OBSERVATIONAL STUDY. Subjects . Patients with
CHF secondary to LVSD (LV ejection fraction #50%)
with persistent symptoms on exertion and a CRT
device, implantable cardioverter-deﬁbrillator, or
standard pacemaker for at least 3 months wereresearch grant from Medtronic. Dr. Paton has received an NIHR
nded by a Leeds Charitable Foundation fellowship. Dr. Cubbon h
Dr. Kearney has received research grants from Medtronic; and is
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received May 22, 2017; revised manuscript received August 31, 2recruited (Leeds NIHR Cardiovascular Clinical
Research Facility, Leeds Teaching Hospitals NHS
trust, Leeds, United Kingdom). Patients also had to be
taking optimally tolerated medical therapy with no
change in medication or other invasive cardiac pro-
cedures for at least 3 months. We also enrolled an
unselected consecutive group of patients with a
standard pacemaker, normal atrioventricular con-
duction, no evidence of heart failure, and normal
echocardiographic ﬁndings as a control group.
Information was collected on comorbidities, past
medical history, medication, pacemaker settings, and
New York Heart Association functional class. All pa-
tients gave written informed consent, and the study
was approved by the local ethics committee and
registered on clinicaltrials.gov (Bowditch Revisited:
Deﬁning the Optimum Heart Rate Range in Chronic
Heart Failure; NCT02563873).
Echocardiographic techniques. Full baseline echocardi-
ography was carried out with gray-scale and tissue
Doppler images recorded in 2- and 4-chamber views
by using harmonics to improve border deﬁnition if
necessary (GE Vivid E95, GE Healthcare, Milwaukee,
Wisconsin). Further images were recorded at each 15-
beat frequency increase during the incremental pac-
ing protocol. Images were stored in the EchoPAC
digital imaging system (GE Healthcare) and analyzed
off-line. This analysis included a calculation of LV
end-diastolic volume and LV end-systolic volume
(LVESV) that used the biplane disks (modiﬁed Simp-
son) method by tracing the endocardial border,
excluding the papillary muscles (11). An average of 3
measurements was used in the ﬁnal analysis. The
frame at the R-wave was taken as end-diastole, and
the frame with the smallest LV cavity was considered
to represent end-systole. The LVESV index (LVESVI)
was calculated at each stage as LVESV/body surface
area, where body surface area was calculated using
the Mosteller equation (12).
Blood pressure measurement . Calculation of the
end-systolic pressure-volume relationship requires
measurement of the LV pressure at end-systole
(13,14). Systolic blood pressure (SBP) measured with
a manual blood pressure cuff was used as a surrogate
for end-systolic LV pressure. Blood pressure re-
cordings were made using a sphygmomanometer and-Integrated Clinical Academic fellowship award. Dr.
as received a British Heart Foundation intermediate
also a British Heart Foundation Professor of Cardi-
thors have reported that they have no relationships
017, accepted September 10, 2017.
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107a standard stethoscope coinciding with echocardio-
graphic images at each HR stage. SBP was recorded at
the point where the ﬁrst tapping sound (phase 1
Korotkoff) occurred for 2 consecutive beats (15).
Pac ing protocol . Echocardiographic images were
collected at rest, after which atrial pacing was initi-
ated in the DDD-mode (or VVI in patients with atrial
ﬁbrillation) for CRT-treated patients and in the AAI-
mode (or DDD with long atrioventricular delays to
avoid right ventricular pacing, or VVI for patients in
atrial ﬁbrillation) for subjects without CRT, at the
lowest multiple of 10 above baseline. After 4 min, a
further set of echocardiographic images was recor-
ded, and subsequently the pacing rate increased in
stepwise 15-beat intervals with images recorded after
every 4 min. This was repeated until the maximum
predicted HR predicted by Åstrand (220  age) was
reached. At this point peak data were collected, and
pacing was returned to baseline settings. For safety,
subjects were asked to remain in the research facility
for a further 30 min.
Force- f requency ca lcu lat ion . Dividing the SBP by
the LVESVI (SBP/LVESVI) gives a surrogate of
contractility (16–20), which has been validated
against invasive methods (15,19). In our protocol, we
repeated these measures at a series of HR stages
(induced by pacing) to allow us to plot the FFR. The
slope of this relationship was then calculated as the
ratio between SBP/LVESVI change from baseline and
HR increase from baseline. We deﬁned the HR at
which, in a biphasic pattern, the SBP/LVESVI reached
maximum value or that beyond the SBP/LVESVI
declined by 5% as the “critical HR.” In a negative FFR
(in cases where there was no increase in contractility
with increments in HR), baseline HR was deemed the
critical HR (21).
Reproduc ib i l i ty . Each image set was anonymized
and reported by a second echocardiographer for
interoperator reproducibility. For intraoperator
reproducibility, each image set was also reported a
second time by the initial reporter. For each dataset,
we documented the HR at which peak contractility
was reached (the critical HR), peak contractility itself,
and the slope of the FFR as described earlier.
RANDOMIZED CONTROLLED TRIAL. Patients with
CHF who were included in the observational phase of
the study were subsequently invited to participate in a
double-blind, randomized, crossover treadmill-based
study comparing exercise time under conventional
rate-response settings with rate-response settings
taking into account the data from the FFR assessment.
An unselected subgroup was invited to attend a third
(blinded) exercise test with ﬁxed-rate pacing.Exc lus ion cr i ter i a . For this part of the investiga-
tion, we invited patients who had participated in the
ﬁrst study and who did not have peripheral vascular
disease or noncardiac conditions such as signiﬁcant
airway disease and musculoskeletal abnormalities
that could restrict walking on a treadmill.
Laboratory ar rangement and exerc i se protocol .
Subjects recruited to this randomized crossover study
were present on 2 (or 3) consecutive occasions at the
same time of day 1 week apart. Before each test, the
pacemaker was interrogated, and patients were then
randomly assigned to the following: rate-adaptive
pacing with conventional age-determined settings
(22); optimized settings on the basis of the results of
their FFR assessment; speciﬁcally limiting the rate-
response algorithm to the critical HR; or, for pa-
tients agreeing to do a third test, ﬁxed-rate pacing
with rate-response settings to “off.”
Subjects were exercised using the ramping tread-
mill protocol (23). Expired air was collected,
and metabolic gas exchange analysis was performed
(Ultimo CardO2, Medical Graphics, St. Paul, Minne-
sota) throughout the test. HR (beats/min), oxygen
uptake (VO2) (ml/kg/min), and carbon dioxide output
(VCO2) (ml/kg/min) were recorded as 15-s averages.
Anaerobic threshold was calculated using the V-slope
method.
The cardiopulmonary exercise test equipment was
recalibrated using manufacturer-recommended vol-
ume and gas calibration techniques before each test.
All test subjects were encouraged to exercise to
exhaustion, and no further motivation or instructions
were given. The arrangement of the laboratory to
ensure double blinding has been described previously
(24). To maintain blinding, the continuous 12-lead
electrocardiogram monitor was obscured throughout
the test (and recovery phase) from subjects and the
supervising physician. Only the unblinded cardiac
physiologist was aware of the programming mode or
testing arm. The unblinded cardiac physiologist
monitored the electrocardiogram throughout the
study, communicated only with the other team
members unless there were safety concerns, and
reprogrammed the pacemaker to its original settings
at the end of every visit.
SAMPLE SIZE CALCULATION. Observat iona l s tudy .
Previous studies exploring contractility in patients
with heart failure were able to demonstrate signiﬁ-
cance using heart failure cohorts of 11  4 subjects and
control cohorts of 83 subjects (25).Henceweaimed to
recruit at least 12 subjects as our “control” population.
Randomized contro l led tr ia l . The primary
endpoint of this study was change in exercise time,
TABLE 1 Subject Demographics at Baseline Visit
Non-HF
(n ¼ 15)
HF Patients
(n ¼ 90) p Value*
Male 14 (93) 79 (88) 0.53
Age, yrs 71.1  16.0 73.5  8.9 0.39
Ischemic heart disease 2 (13) 54 (60) 0.0008
Diabetes mellitus 4 (27) 28 (31) 0.73
BSA, m2 1.9  0.1 2.0  0.2 0.07
NYHA functional class 0.0001
I 15 (100) 1 (1)
II n/a 70 (78)
III n/a 19 (21)
Beta-blockers 3 (20) 82 (91) 0.0001
ACE inhibitor/ARB 3 (20) 77 (86) 0.0001
Furosemide dose, mg/day 0 47 (26)
Digoxin 0 (0) 15 (17) 0.084
AA 0 (0) 38 (42) 0.001
Device (PPM/ICD/CRT) n/a 14/9/67 (16/10/74)
Atrial ﬁbrillation 3 (20) 25 (28) 0.51
LVEF, % 55.6  5.3 33.3  10.8 0.0001
Critical heart rate, beats/min 126  15 103  22 0.0002
Peak contractility, SBP/LVESVI 9.8  4.1 3.8  3.7 0.0001
Force-frequency relationship† 0.054  0.042 0.011  0.028 <0.0001
Values are n (%) or mean  SD. *p values are from unpaired Student t tests or chi-squared tests as appropriate.
†From likelihood ratio test in linear mixed model.
AA ¼ aldosterone antagonist; ACE ¼ angiotensin-converting enzyme; ARB ¼ aldosterone receptor blocker;
BSA ¼ body surface area; CRT ¼ cardiac resynchronization therapy; HF ¼ heart failure; ICD ¼ implantable
cardioverter-deﬁbrillator; LVEF¼ left ventricular ejection fraction; LVESVI¼ left ventricular systolic volume index;
n/a ¼ not applicable; NYHA ¼ New York Heart Association functional class; PPM ¼ permanent pacemaker;
SBP ¼ systolic blood pressure.
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108with a secondary endpoint of peak oxygen con-
sumption. On the basis of guidelines for pilot studies
(26,27), and accounting for a dropout rate of 20%, we
aimed to recruit 28 patients to achieve 20 participants
with complete data.equency Relationship in Patients and Controls
tile response (as described by the ratio of systolic blood pressure
ar end-systolic volume index [LVESVI]) to heart rate rise in
heart failure compared with control subjects. Values are mean
erval).Stat i st i ca l ana lys i s . Data were analyzed using the
Statistical Package for the Social Sciences SPSS
version 21 (IBM Corp., Armonk, New York), R: A
Language and Environment for Statistical Computing
version 3.2.3 (R Development Core Team, Vienna,
Austria), and SAS version 9.4 (SAS Institute, Inc.,
Cary, North Carolina).
Normality for all continuous variables was tested
using the Shapiro-Wilk test. Normally distributed
continuous variables were reported as mean and
mean  SD, and non-normally distributed continuous
variables were reported as median (interquartile
range). Subsequently, associations between groups or
interventions and baseline characteristics were
assessed using either analysis of variance and the
2-sample Student t test for normally distributed
values or the Kruskal-Wallis H test (1-way analysis of
variance of ranks) for non-normally distributed data.
Similar associations with categorical variables were
analyzed using the chi-squared test for contingency
tables.
Once a familiarization test has been performed, a
peak exercise test is not a training stimulus. We pre-
viously performed up to 5 exercise tests in consecu-
tive weeks in patients with CHF and controls, with no
longitudinal effects (28). However, to account for any
carryover effects, the interventional crossover study
was analyzed using a linear mixed model with a
random effect for subject. For each endpoint Yak (e.g.,
exercise time) under consideration in the study:
Yak ¼ mþ di þ pj þ in þ ak þ ink
where ink w N (0, s2ε), ak w N (0, s2a) and m is the
overall mean, s is the treatment effect, p is the period
effect, and l is the carryover effect (which is mathe-
matically identical to an interaction term between
treatment and period). This model was estimated
using PROC MIXED in SAS, and least squares means
were estimated for each of these terms and their
differences.
All statistical tests were 2-sided, and any
p value <0.05 was called statistically signiﬁcant.
Ethical approval for both phases of the investiga-
tion was granted by the Health Research Authority
(National Research Ethics Service Centre: Yorkshire
and the Humber REC: 12/YH/0097). Written informed
consent was obtained from all participants. The
crossover study was registered on clinicaltrials.gov
(NCT02563873) before any patient enrollment.
RESULTS
OBSERVATIONAL STUDY. We enrolled 90 patients
with CHF and 15 control subjects with normal LV
FIGURE 2 Peak Contractility by Levels of Left Ventricular Dysfunction
The greater impairment of peak contractility (as described by the ratio of SP to LVESVI) in
response to heart rate rise in patients with more severe left ventricular systolic
dysfunction (1-way analysis of variance p < 0.0001). Abbreviations as in Figure 1.
TABLE 2 Baseline Variables of Patients Enrolled in the
Randomized, Controlled, Crossover Trial (N ¼ 52)
Male 44 (85)
Age, yrs 73.8  9.6
Etiology
Ischemic heart disease 33 (63)
Diabetes mellitus 15 (29)
BSA, m2 2.0  0.2
NYHA functional class
I 0 (0)
II 43 (83)
III 9 (17)
Beta-blockers 47 (90)
ACE inhibitor/ARB 47 (90)
Furosemide dose, mg/day 43  24
Digoxin 6 (12)
AA 21 (40)
Device (CRT/ICD) 50/2 (96/4)
Atrial ﬁbrillation 15 (29)
LVEF, % 32  11
Critical heart rate, beats/min 101  19
Peak contractility, SBP/LVESVI 3.4  2.0
Values are n (%) or mean  SD.
Abbreviations as in Table 1.
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109function into the ﬁrst phase of the study. Baseline
clinical, echocardiographic, and pacemaker variables
are shown in Table 1. We were able to establish the 3
key variables of peak contractility, critical HR, and
the slope of the relationship between HR and
contractility in all patients.
Patients with CHF had lower mean peak contrac-
tility, lower mean critical HR, and a lower slope of the
relationship between HR and contractility below the
critical HR (the FFR) than control subjects (Table 1,
Figure 1).
Separate models were required for each group, as
compared with considering the data overall. This was
conﬁrmed by a likelihood ratio test for a saturated
model compared with a simple additive model for HR,
HR2, and patient group (chi-square test ¼ 214.63;
p < 1015). Further examining the relationship in
linear mixed effects models showed that there was
little evidence of a quadratic relationship in each
group of patients:
 Controls: 0.2915604 þ 0.0844503  HR 
0.00017  HR2
 CHF: 1.971 þ 7.170e03 þ 2.510e05  HR2
In the controls, the linear term was signiﬁcant
(p < 0.05), and the quadratic term showed weak
evidence of being required (p ¼ 0.15). However, for
CHF the linear term was not signiﬁcant (p ¼ 0.334),
and the quadratic term was not signiﬁcant (p ¼ 0.525).
Considering the linear terms, in controls, for every
10 beats/min increase in HR there was a 0.8-unit
increase in contractility. For the patients with CHF,
this relationship was signiﬁcantly less, at <0.02.
The Strand formula calculated a higher peak HR
than the calculated critical HR for all except 1 CHF
patient (mean HR 146  9.0 vs. 103  22; p < 0.0001),
and all but 3 control subjects (149  16 vs. 126  15;
p ¼ 0.002). The inaccuracy of the Strand formula in
beats perminutewas greater in patients than in control
subjects (43  24 vs. 23  24; p ¼ 0.0039). Age was
unrelated to any of the measures of cardiac function
including contractility, and there was no relationship
between critical HR and resting LV function in either
group. However, in patients with CHF, there was a
strong correlation between peak contractility and
baseline ejection fraction (0.50; 95% conﬁdence in-
terval: 0.33 to 0.64; p < 0.0001) (Figure 2).
Reproduc ib i l i ty . The linear mixed effects models
allowed direct assessment of the reproducibility of
the reading of the echocardiograms by different
operators through components of variance. The per-
centage of variation in the models for controls and
CHF attributed to the contractility measurement bydifferent operator or repeated assessment by the
same operators was <1% of variance.
INTERVENTIONAL STUDY. A total of 52 patients were
enrolled in this study (Table 2). Baseline clinical and
echocardiographic variables of this subgroup were
not different from those of patients enrolled in the
TABLE 3 Exercise Variables in 52 Patients With Heart Failure During Conventional and Optimized Heart Rate Programming
Programming Mean
95% Conﬁdence
Interval
Mean
Difference
95% Conﬁdence
Interval p Value
Exercise time, s Tailored 474.74 (420.69 to 528.79) 49.85 (18.41 to 81.29) 0.0025
Not tailored 424.89 (370.84 to 478.94)
Peak VO2, ml/kg/min Tailored 17.31 (16.00 to 18.62) 0.75 (0.16 to 1.34) 0.0134
Not tailored 16.56 (15.25 to 17.87)
O2 pulse Tailored 13.39 (12.33 to 14.45) 3.21 (2.33 to 4.08) <0.0001
Not tailored 10.19 (9.13 to 11.25)
VEVCO2 slope Tailored 31.80 (29.81 to 33.78) 1.89 (3.38 to 0.40) 0.0139
Not tailored 33.69 (31.70 to 35.67)
Peak RER Tailored 1.01 (0.99 to 1.04) 0.00 (0.03 to 0.02) 0.7456
Not tailored 1.02 (0.99 to 1.05)
Peak heart rate, beats/min Tailored 109.11 (106.01 to 112.21) 28.88 (32.83 to 24.93) <0.0001
Not tailored 137.99 (108.87 to 167.12)
O2 ¼ oxygen; RER ¼ respiratory exchange ratio; VE/VCO2 slope ¼ relationship between ventilation and carbon dioxide output; VO2 ¼ oxygen consumption.
FIGURE 3 Results of the Randomized, Placebo-Controlled Double-Blind Crossover Study of Tailored Versus
Standard Rate-Response Programming
(A) Greater exercise time with tailored programming. (B) Higher peak oxygen consumption with tailored programming. (C) Greater oxygen
pulse with tailored programming. (D) Lower heart rate with tailored rate-response programming. All values are mean (95% conﬁdence
interval). HR ¼ heart rate; O2 ¼ oxygen.
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111observational study. Of these 52 patients, 12 under-
went a third test with ﬁxed-rate pacing.
Table 3 and Online Table 1 show the exercise vari-
ables for conventional and optimized HR rise tests.
Optimized settings were associated with improved
exercise time, peak oxygen consumption, oxygen
pulse, and lower VET/VCO2 slope, whereas HR was
lower and respiratory exchange ratio was the same
despite a small period effect (Figures 3A to 3D).
Fixed-rate pacing in 12 unselected patients led to
similar exercise times as Strand-guided conventional
rate-response pacing (Online Figures 1A to 1C).
Furthermore, there was no heterogeneity in the
beneﬁts of tailored programming between patients
with and without diabetes mellitus, those with and
without atrial ﬁbrillation, and those with and without
ischemic heart disease (Online Tables 2 to 4).
DISCUSSION
Our study demonstrates that patients with CHF have
an impaired force-frequency curve compared with
controls that can easily be assessed using a nonin-
vasive, reproducible echocardiographic method and
that peak contractility is related to the baseline
cardiac function. We have also shown that using
the data from the force-frequency curve in patients
with CHF allows us to tailor pacing algorithms tar-
geting the critical HR and leads to a signiﬁcant
improvement in exercise time and peak oxygen
consumption.
Rate-adaptive cardiac pacing, whereby HR is
increased in response to movement or ventilation
detected by internal device sensors, was developed as
an attempt to treat exercise intolerance thought to
result from chronotropic incompetence (29,30). The
settings are broadly based on a series of experiments
to describe maximal HR and age in healthy adults
(31–33). Although there are numerous published
datasets describing maximal HR changes with aging
(34–37), the “Strand formula” (220  age), which in
itself is an extrapolation of data from various sour-
ces, remains the most frequently used. However, all
datasets are taken from healthy individuals exer-
cising to physiological maximum. In patients without
CHF who are receiving standard pacemakers for
bradycardia, rate-adaptive programming on the basis
of a simple, age-related algorithm is associated with
an increase in cardiac output during exercise (38),
and better quality of life (39–41), but inconsistent
improvements in exercise capacity (42,43), compared
with ﬁxed-rate pacing.
We have demonstrated that chronotropic incom-
petence as determined by the standard equationseems not to be a limiting factor in maximal perfor-
mance in patients with CHF (17,44,45), because con-
ventional rate-adaptive pacing in patients with CHF
does not improve exercise capacity compared with
ﬁxed-rate pacing (17). Furthermore, we and other in-
vestigators have shown that rate-adaptive pacing
may worsen prognosis and cardiac function (46,47).
The reason for the failure of increments in HR to
increase exercise capacity in patients with CHF may
be that conventional rate-adaptive pacing algorithms
do not take into account the altered cardiac contrac-
tile function in CHF.
Increased contractility during exercise is thought
to be important to maintain stroke volume in the
presence of impaired ﬁlling during higher HRs. The
FFR is abnormal in CHF such that contractility does
not rise normally with increases in HR. In agreement
with this, in our cohort of unselected, optimally
managed patients with CHF secondary to LVSD, we
demonstrated a consistent and reproducible impair-
ment of the FFR with a lower critical HR, lower peak
contractility, and a lower FFR slope than in subjects
without CHF.
We hypothesized that noninvasive assessment of
the FFR could provide a physiologically relevant
descriptor of the optimal HR range and peak HR that
could be used to optimize rate-response programming
patients with CHF. To examine this we performed a
randomized, double-blind, placebo-controlled cross-
over study of optimized rate-response programming
versus conventional rate-response programming in
patients with CHF to examine this concept. Our study
showed that this precision-approach rate-adaptive
programming can acutely improve treadmill
exercise time and peak oxygen consumption. This
approach represents a paradigm in rate-responsive
pacing for patients with CHF in which the pace-
maker rate-response settings are personalized to work
in synergy with and take advantage of intrinsic car-
diac physiology.
STUDY LIMITATIONS. Our observational study has
biases that are common in studies of this type. There
is a degree of patient selection in that those patients
who are too unwell with advanced CHF or who have
other comorbidities may be less keen to participate in
clinical research.
The age of our non-CHF group was similar to that
of our CHF group, and some patients were taking
angiotensin-converting enzyme inhibitors and beta-
adrenoceptor antagonists for hypertension. We do
not believe that this materially altered our ﬁndings.
Our methodology restricted us to patients with
pacemaker devices, who may exhibit a different
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Noninvasive assessment of contractility is
reproducible and identiﬁes a physiological HR range
target to which to program a pacemaker. This
precision programming improves exercise time in
patients with CHF. Optimizing pacemaker settings on
the basis of a simple and reproducible noninvasive
assessment of the FFR in patients with heart failure
can improve exercise capacity.
TRANSLATIONAL OUTLOOK: This investigation
shows that carefully assessing patients’ physiolog-
ical response to increased HRs can be directly
translated into clinical beneﬁts while also providing
a potential mechanism for the lack of beneﬁt of
conventional rate-response programming in patients
with CHF.
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112contractile response to increased HRs than patients
without a pacemaker device.
We cannot exclude the possibility of systematic
differences in the level of motivation or encourage-
ment from the technicians running the tests at
different time points. However, we believe that the
randomization and double-blind study design will
have removed any signiﬁcant bias. Our blinding pro-
cedure has worked well in previous reports (24).
Although we deﬁned a pre-speciﬁed signiﬁcance level
for rejecting hypotheses for the primary endpoint, no
multiple testing control was applied to the secondary
endpoints. Therefore all results determined on the
basis of secondary endpoints should be considered as
hypothesis generating.
We used the ramping treadmill protocol to be
consistent for all patients, to allow us to compare
exercise times rather than just metabolic gas analysis
data, and because treadmill-based activity is associ-
ated with greater upper body movement required for
activation of the rate-response algorithms in pace-
makers. We acknowledge that this exercise modality
and protocol may not have been ideal for all of our
patients, but on balance we doubt that the protocol
choice materially altered our results. The early, low-
workload stage allowed even those patients with the
greatest limitation in exercise capacity to complete at
least the ﬁrst stage, thereby reducing the bias toward
less limited patients.
Our FFR data were collected with patients in the
supine position, and the exercise testing on the
treadmill was upright. This positioning has the po-
tential to alter loading conditions, which could have
an effect on the critical HR. However, upright echo-
cardiography has an adverse effect on image quality
and patient comfort (48,49). Furthermore, the Bow-
ditch phenomenon as originally described and its
mechanism are purported to be loading independent.
Finally, our data were collected immediately
following pacemaker reprogramming during 2 (3)
visits to the NIHR Leeds Cardiovascular Clinical
Research Facility at Leeds Teaching Hospitals NHS
Trust, and pacing was reset to nominal values
for each patient at the end of the visit. Whetherlonger-term rate-response optimization tailored for
the FFR data is safe and has beneﬁcial effects on ex-
ercise capacity remains to be proven.
CONCLUSIONS
We have demonstrated that a reproducible, nonin-
vasive assessment of the FFR is possible in patients
with a pacemaker and that using these data to
personalize the rate-response settings of the pace-
maker can improve exercise time in patients with
CHF and LVSD.
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